Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LPL | P06858 | 4/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL319623 | 0.88 | P2RX7 (0.52) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL22626216 | 0.75 | P2RX7 (0.39) | P2RX7MAPK1 | |
| SCHEMBL24350060 | 0.74 | — | — | |
| SCHEMBL18797411 | 0.73 | MAPK1 (0.38) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL19436674 | 0.72 | MAPK1 (0.37) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL18010895 | 0.69 | P2RX7 (0.56) | P2RX7MAPK1 | |
| SCHEMBL18010894 | 0.69 | P2RX7 (0.56) | P2RX7MAPK1 | |
| SCHEMBL570904 | 0.68 | P2RX7 (0.56) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL30965858 | 0.67 | P2RX7 (0.80) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL20867989 | 0.67 | MAPK1 (0.71) | P2RX7MAPK1LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727941-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| US-20250276966-A1 | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | PFIZER (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250122183-A1 | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | PFIZER (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025074249-A1 | NITROGEN-LINKED BENZISOXAZOLE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | PFIZER INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-2024255885-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-12-19 | — | — | WO | disclosed |
| EP-4430036-A2 | BCAT2 INHIBITORS | Agios Pharmaceuticals, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-117355508-A | Heterocyclic derivative and application thereof in medicine | 西藏海思科制药有限公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-2023220741-A1 | ALPHA 4 BETA 7 INTEGRIN MODULATORS AND USES THEREOF | DICE MOLECULES SV, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-11721838-B2 | Electrolyte and electrochemical apparatus | NINGDE AMPEREX TECHNOLOGY LIMITED (CN) | 2023-08-08 | — | — | US | disclosed |
| US-11721838-B2 | Electrolyte and electrochemical apparatus | NINGDE AMPEREX TECHNOLOGY LIMITED (CN) | 2023-08-08 | — | — | US | disclosed |
| US-20140288043-A1 | PYRAZOLOPYRIDINE COMPOUNDS | GENENTECH, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| EP-2328903-B1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2014-03-05 | — | — | EP | disclosed |
| WO-2013139882-A1 | PYRAZOLOPYRIDINES FOR TREATMENT OF PARKINSONS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-09-26 | — | — | WO | disclosed |
| US-8426447-B2 | Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2547685-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | Amgen Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011115938-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | AMGEN INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| EP-2328903-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010030954-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288043-A1 | PYRAZOLOPYRIDINE COMPOUNDS | KCNJ11, P2RX4, P2RY4 | P2RX7 17/4885MAPK1 270/4885LPL 3929/4885 |
| US-20250122183-A1 | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | CCNI, MKI67, CCNA1 | P2RX7 839/4885MAPK1 2624/4885LPL 4883/4885 |
| US-20250276966-A1 | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | CCNI, MKI67, CCNA1 | P2RX7 892/4885MAPK1 2842/4885LPL 4883/4885 |
| US-11721838-B2 | Electrolyte and electrochemical apparatus | HCN2, HCN3, KCNH3 | P2RX7 3181/4885MAPK1 1553/4885LPL 4442/4885 |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | P2RX7 1520/4885MAPK1 3616/4885LPL 1651/4885 |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | P2RX7 2223/4885MAPK1 3186/4885LPL 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.